SELLAS Life Sciences Group, Inc. Email Format

Biotechnology ResearchNew York, United States11-50 Employees

SELLAS Life Sciences Group, Inc. operates in the biotechnology research sector as a late-stage clinical biopharmaceutical company focused on developing cancer therapies. The company is headquartered in New York, at 7 Times Square, Suite 2503, New York, NY 10036, and employs 11 to 50 people. Its lead candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein across multiple tumor types; its second candidate, GFH009, is a selective CDK9 inhibitor licensed from GenFleet Therapeutics with exclusive rights to develop and commercialize outside greater China. GPS and GFH009 are being pursued as monotherapies or in combination with other treatments for a range of hematologic malignancies and solid tumors. The company also advances SLS009, another CDK9 inhibitor, with recent activity including preclinical data presentation at the 2026 AACR conference, ASH 2025 data presentations, and Europe expansion to support the SLS009 program.

Sign up for free to view info

Company overview Employee directory